An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingGSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesisCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsTherapeutic Implications of Targeting AKT Signaling in MelanomaGSK-3 as potential target for therapeutic intervention in cancerWho needs microtubules? Myogenic reorganization of MTOC, Golgi complex and ER exit sites persists despite lack of normal microtubule tracksSimilar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesStructure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and SelectivityExtremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF KinaseStructure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3βTargeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesIn vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerRuthenium anticancer compounds: myths and realities of the emerging metal-based drugs.Identification of glycogen synthase kinase 3α as a therapeutic target in melanomaMolecular pathogenesis of sporadic melanoma and melanoma-initiating cells.FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.Ruthenium-based chemotherapeutics: are they ready for prime time?Ubiquitin proteasomal pathway mediated degradation of p53 in melanomaPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionMirror-image organometallic osmium arene iminopyridine halido complexes exhibit similar potent anticancer activity.Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.Development of organometallic S6K1 inhibitors.Melanoma: Molecular Pathogenesis and Therapeutic ManagementE2F1-dependent oncogenic addiction of melanoma cells to MDM2.Targeting mutant p53 shows promise for sunscreens and skin cancerp63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.Skp2 regulates G2/M progression in a p53-dependent mannerNew trends for metal complexes with anticancer activityAdaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma.Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization.The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytesThe role of p53 in pigmentation, tanning and melanoma.Bioorganometallic chemistry--from teaching paradigms to medicinal applications.Application of metal coordination chemistry to explore and manipulate cell biology.The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.Small molecules and targeted therapies in distant metastatic disease.Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.
P2860
Q21133611-8FEBF22E-8BFA-448B-9114-562F4CFE23BBQ24319759-71589B91-DE51-4318-9A6C-943A39FE2789Q24618486-BF97DDC0-BC1E-44C3-B03F-A17FB87F2D38Q24631438-FFFB1AE4-6C91-4D88-B965-0F66425B8AA6Q27013811-3AAB5ABB-DEC6-4BF2-8A4F-D2386E36B686Q27311038-9D5FA248-2963-4919-8E39-C2437EA4A755Q27650404-0FB6403C-200E-4305-8D4A-BA31F908CBAAQ27650628-5AAB39E3-3261-4E44-BEDC-17AA0D210DC9Q27652994-621D1AB0-0A62-4038-B02A-2758296BAC6FQ27654846-42A1A253-BF70-4618-B1D5-17E1CFFBB066Q27664286-89A5FFB8-E29D-494F-BDDD-901FFA7967D8Q27853201-C1FC6F20-6BCD-4716-84D7-82681F9389DBQ30398565-54B9356E-6F36-4F3C-91C8-4F5A776681FBQ30403317-9F734E5D-7FB5-42F1-80A2-698E9B8B8082Q33569998-E9C05CCB-2AB0-4A0C-9750-B77B3A6C7405Q33725172-9DF00C17-1B04-4D67-8F26-720F22CA0E52Q33767083-CB433665-B690-4D25-BAA2-A3F5553CCF13Q33906093-5FDF85C2-1279-4973-AD7D-CB224B54613EQ33989444-26C49126-9934-42FD-971D-2B107DC479F1Q34102818-D96BDC7C-3AA2-4CC7-8C3C-A69C0B789E0AQ34699448-7FEBAEDA-F01B-40AA-B95A-A81FAF07D325Q34761941-10BB2742-FBAE-489A-98E4-24938159CDD7Q34795234-71DD7F41-662D-4D70-BCE7-5E9F1B86DF4BQ34838275-EE4E72A5-24ED-46BC-8B43-07FC351660E9Q34891733-2726206D-1626-463E-8608-0F6C869382E5Q35137163-8C3EB608-6EF1-48E2-949D-F98B977D132BQ35353609-895793DE-8667-4CB3-9D6E-4A42A7B95A53Q36173619-F935E0C9-B05E-4A44-BE88-90D2D799FE0FQ36694173-285EDFF8-9EEE-47E4-8DA2-F315E61CB1EFQ36954187-5DD0E418-B564-42C1-882F-C639F77B8EF5Q37044080-6E81CCA8-5057-42F5-A5E3-CED723B78111Q37162535-41C101D7-B523-4208-9190-77587BB9FB49Q37188981-18536ED0-737E-46A1-A4EF-9A0F7DA70BFDQ37197419-A8412B24-A748-460B-9E30-05796CEF6F66Q37257745-C73083E7-069A-4F3E-92D8-896C73611A1DQ37377528-4E02B052-2524-4107-BA57-0A4E279ECFE2Q37387617-65937C5E-A1B0-4DEF-9319-E0BFF5DA5A39Q37506648-1320395E-9627-4DD5-94BC-81C4009DFE36Q37555793-3B87C51F-2100-470F-A027-3FE129C8E3D9Q37603642-558A0F5D-869F-49B9-8E4A-3E9F0D8F0EAB
P2860
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
An organometallic protein kina ...... tosis in human melanoma cells.
@en
An organometallic protein kina ...... tosis in human melanoma cells.
@nl
type
label
An organometallic protein kina ...... tosis in human melanoma cells.
@en
An organometallic protein kina ...... tosis in human melanoma cells.
@nl
prefLabel
An organometallic protein kina ...... tosis in human melanoma cells.
@en
An organometallic protein kina ...... tosis in human melanoma cells.
@nl
P2093
P50
P1433
P1476
An organometallic protein kina ...... tosis in human melanoma cells.
@en
P2093
Angela N Kulp
Douglas S Williams
Eric Meggers
G Ekin Atilla-Gokcumen
Howard Bregman
Maria S Soengas
Nikolas K Haass
Rooha Contractor
P304
P356
10.1158/0008-5472.CAN-06-1538
P407
P577
2007-01-01T00:00:00Z